Status:
RECRUITING
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Cutaneous Melanoma
Cutaneous Melanoma, Stage III
Eligibility:
All Genders
18+ years
Brief Summary
The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form...
Detailed Description
PRIMARY OBJECTIVES: 1. Evaluate for changes over time in the patients' symptom experience, 2. Identify distinct symptom profiles over time. 3. Evaluate for demographic, clinical, environmental, and m...
Eligibility Criteria
Inclusion
- Adults ≥18 years of age
- Able to speak and read English
- Diagnosed with stage IIB, III, or IV cutaneous melanoma
- Participants who are scheduled to receive \>=1 immune checkpoint inhibitor at University of California San Francisco medical center locations. Participants on targeted therapies (e.g., BRAF or mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors) will be eligible.
- Provide written informed consent to participate in this study.
- Participants with stage IIB or higher cutaneous melanoma
Exclusion
- Participants will be excluded if they are unable to complete study requirements.
Key Trial Info
Start Date :
October 13 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT07148245
Start Date
October 13 2025
End Date
June 30 2027
Last Update
November 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143